Form 483

Medtronic Navigation, Inc. Form 483, 2010-02-04

FDA issued a Form 483 to Medtronic Navigation, Inc. on 2010-02-04 with 9 public-safe observations.

483· Form 483 issued9 observations

Medtronic Navigation, Inc. · Lafayette, United States · Issued February 4, 2010

Overview

  • 9 public-safe observations are available for this inspection.
  • 9 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

4 Feb 2010
21 CFR 803.52(a)(1)

Patient Name or Other Identifier

Cited by Bryan J Love

4 Feb 2010
21 CFR 803.56

Submission Within One Month

Cited by Bryan J Love

4 Feb 2010
21 CFR 820.30(a)

Design control - no procedures

Cited by Bryan J Love

4 Feb 2010
21 CFR 820.30(d)

Essential design outputs

Cited by Bryan J Love

4 Feb 2010
21 CFR 820.30(g)

Design Validation - Risk analysis not performed/inadequate

Cited by Bryan J Love

Inspected site

MNMedtronic Navigation, Inc.Lafayette, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 803.52(a)(1)Cited across public-safe Form 483 observations1x
21 CFR 803.56Cited across public-safe Form 483 observations1x
21 CFR 820.100(a)(2)Cited across public-safe Form 483 observations1x
21 CFR 820.198(a)Cited across public-safe Form 483 observations1x
21 CFR 820.198(a)(3)Cited across public-safe Form 483 observations1x
21 CFR 820.30(a)Cited across public-safe Form 483 observations1x
21 CFR 820.30(d)Cited across public-safe Form 483 observations1x
21 CFR 820.30(g)Cited across public-safe Form 483 observations1x
21 CFR 820.80(d)(1)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 9 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere